Fulfilling the biosimilar promise: European report

Biosimilar medicines provide a tremendous opportunity for governments throughout Europe to increase patient access to treatment with modern biologic therapies while at the same time supporting the sustainability of healthcare budgets.

These benefits will however only continue provided the biosimilar medicines market is developed in a sustainable way. The cornerstone of a sustainable biosimilar medicines market is the alignment of payers’ and manufacturers’ understanding of the benefits in both the short and long terms, a new report revealed today.

The research, undertaken by Simon Kucher & Partners on behalf of the Biosimilar Medicines Group, a Medicines for Europe sector group, takes a deep dive into biosimilar medicines pricing and market access policies across seven European countries (Germany, Spain, France, Italy, Norway, Poland and the UK) and their impact on parameters such as biosimilar medicines use and price. Through a detailed analysis of today’s biosimilar medicines landscape, combined with interviews with payers, policy makers and industry representatives, Simon Kucher & Partners were able to develop principles supporting a sustainable biosimilar medicines market, taking into account the perspective of both payers and manufacturers.